Trial record 1 of 1 for:    A Phase III Randomized, Double-Blind Trial of Chemoembolization with or without Sorafenib in Unresectable Hepatocellular Carcinoma (HCC) in Patients with and without Vascular Invasion
Previous Study | Return to List | Next Study

Chemoembolization With or Without Sorafenib Tosylate in Treating Patients With Liver Cancer That Cannot Be Removed by Surgery

This study is currently recruiting participants. (see Contacts and Locations)
Verified October 2014 by National Cancer Institute (NCI)
Sponsor:
Information provided by (Responsible Party):
National Cancer Institute (NCI)
ClinicalTrials.gov Identifier:
NCT01004978
First received: October 29, 2009
Last updated: October 23, 2014
Last verified: October 2014
  Purpose

This randomized phase III trial studies chemoembolization and sorafenib tosylate to see how well they work compared with chemoembolization alone in treating patients with liver cancer that cannot be removed by surgery. Drugs used in chemotherapy, such as doxorubicin hydrochloride, mitomycin, and cisplatin, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Chemoembolization kills tumor cells by carrying drugs directly into blood vessels near the tumor and then blocking the blood flow to allow a higher concentration of the drug to reach the tumor for a longer period of time. Sorafenib tosylate may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. It is not yet known whether giving chemoembolization together with sorafenib tosylate is more effective than chemoembolization alone in treating patients with liver cancer.


Condition Intervention Phase
Adult Primary Hepatocellular Carcinoma
Localized Unresectable Adult Primary Liver Cancer
Recurrent Adult Primary Liver Cancer
Drug: sorafenib tosylate
Other: placebo
Drug: doxorubicin hydrochloride
Drug: doxorubicin-eluting beads
Drug: cisplatin
Drug: mitomycin C
Other: pharmacological study
Other: laboratory biomarker analysis
Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Investigator)
Primary Purpose: Treatment
Official Title: A Phase III Randomized, Double-Blind Trial of Chemoembolization With or Without Sorafenib in Unresectable Hepatocellular Carcinoma (HCC) in Patients With and Without Vascular Invasion

Resource links provided by NLM:


Further study details as provided by National Cancer Institute (NCI):

Primary Outcome Measures:
  • PFS [ Time Frame: Time from randomization to progression or death without evidence of progression, assessed up to 16 months ] [ Designated as safety issue: No ]
    All PFS analyses will use the multi-time point (for the vascular invasion at 4, 8 and 12 months, and the non-vascular invasion group at 8, 12 and 16 months) Cochran-Mantel-Haenszel (CMH) test of Freidlin, et al. with an overall one-sided 0.025 type I error. The p-value from the one-sided multi-time point CMH test will be compared to the truncated O'Brien-Fleming boundary.


Secondary Outcome Measures:
  • Overall survival [ Time Frame: Time from randomization to death from any cause, or last known date of survival, assessed up to 4 years ] [ Designated as safety issue: No ]
    Analyses will use a one-sided logrank test stratified on vascular invasion (yes vs. no) and Child-Pugh Score (A vs. B7), using a one-sided overall type I error of 0.025. Critical values at interim analyses will be determined using a truncated version of the Lan-Demets error spending rate function corresponding to the O'Brien-Fleming boundary.

  • Incidence of adverse events, graded according to National Cancer Institute Common Terminology Criteria for Adverse Events version 4.0 [ Time Frame: Up to 4 years ] [ Designated as safety issue: Yes ]

Estimated Enrollment: 400
Study Start Date: October 2009
Estimated Primary Completion Date: February 2018 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Arm I (sorafenib tosylate and TACE)
Patients receive sorafenib tosylate PO BID in the absence of disease progression or unacceptable toxicity. Beginning within 2 weeks after a stable dose of sorafenib tosylate is reached, patients undergo TACE comprising doxorubicin hydrochloride, mitomycin C, and cisplatin (closed to accrual as of 10/1/2010); conventional chemoembolization comprising doxorubicin hydrochloride only; or chemoembolization comprising doxorubicin-eluting beads. Treatment with TACE repeats approximately every 4 weeks for up to 4 courses in the absence of disease progression or unacceptable toxicity.
Drug: sorafenib tosylate
Given PO
Other Names:
  • BAY 43-9006
  • BAY 43-9006 Tosylate Salt
  • BAY 54-9085
  • Nexavar
  • SFN
Drug: doxorubicin hydrochloride
Undergo TACE
Other Names:
  • ADM
  • ADR
  • Adria
Drug: doxorubicin-eluting beads
Undergo TACE
Drug: cisplatin
Undergo TACE
Other Names:
  • CACP
  • CDDP
  • CPDD
  • DDP
Drug: mitomycin C
Undergo TACE
Other Names:
  • MITC
  • MITO
  • MITO-C
  • Mitocin-C
  • MTC
Other: pharmacological study
Correlative studies
Other Name: pharmacological studies
Other: laboratory biomarker analysis
Correlative studies
Active Comparator: Arm II (placebo and TACE)
Patients receive placebo PO BID in the absence of disease progression or unacceptable toxicity. Beginning within 2 weeks after a stable dose of placebo is reached, patients undergo TACE as in Arm I.
Other: placebo
Given PO
Other Name: PLCB
Drug: doxorubicin hydrochloride
Undergo TACE
Other Names:
  • ADM
  • ADR
  • Adria
Drug: doxorubicin-eluting beads
Undergo TACE
Drug: cisplatin
Undergo TACE
Other Names:
  • CACP
  • CDDP
  • CPDD
  • DDP
Drug: mitomycin C
Undergo TACE
Other Names:
  • MITC
  • MITO
  • MITO-C
  • Mitocin-C
  • MTC
Other: pharmacological study
Correlative studies
Other Name: pharmacological studies
Other: laboratory biomarker analysis
Correlative studies

Detailed Description:

PRIMARY OBJECTIVE:

I. To compare progression-free survival (PFS) of chemoembolization alone to sorafenib (sorafenib tosylate) in combination with chemoembolization.

SECONDARY OBJECTIVES:

I. To compare overall survival (OS) of chemoembolization alone to sorafenib in combination with chemoembolization.

II. To evaluate extra-hepatic versus intra-hepatic patterns of failure. III. To determine the rates of toxicity related to sorafenib in combination with chemoembolization.

TERTIARY OBJECTIVES:

I. To analyze the pharmacogenetic and pharmacokinetic properties of sorafenib including angiogenesis, monooxygenases, polymorphisms and multidrug resistance (MDR).

II. Eastern Cooperative Oncology Group (ECOG)-American College of Radiology Imaging Network (ACRIN) secondary imaging objective: site vs. central evaluation of PFS.

III. To determine the inter-reader concordance for response characterization at four and eight months by the European Association for the Study of Liver (EASL) criteria.

IV. To determine the value of objective tumor response at four and eight months by the EASL criteria to predict PFS (by Response Evaluation Criteria in Solid Tumors [RECIST]) and OS.

V. To evaluate the effects of intra-hepatic vs. extra-hepatic progression on OS.

OUTLINE: Patients are randomized to 1 of 2 treatment arms.

ARM I: Patients receive sorafenib tosylate orally (PO) twice daily (BID) in the absence of disease progression or unacceptable toxicity. Beginning within 2 weeks after a stable dose of sorafenib tosylate is reached, patients undergo transarterial chemoembolization (TACE) comprising doxorubicin hydrochloride, mitomycin C, and cisplatin (closed to accrual as of 10/1/2010); conventional chemoembolization comprising doxorubicin hydrochloride only; or chemoembolization comprising doxorubicin-eluting beads. Treatment with TACE repeats approximately every 4 weeks for up to 4 courses in the absence of disease progression or unacceptable toxicity.

ARM II: Patients receive placebo PO BID in the absence of disease progression or unacceptable toxicity. Beginning within 2 weeks after a stable dose of placebo is reached, patients undergo TACE as in Arm I.

MAINTENANCE THERAPY: After completion of chemoembolization, patients receive sorafenib tosylate or placebo as in Arm I and II in the absence of disease progression or unacceptable toxicity.

After completion of study treatment, patients are followed up for 4 years.

  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Patients must have a diagnosis of hepatocellular carcinoma by at least one criterion listed below:

    • Histologically confirmed
    • Magnetic resonance imaging (MRI) or computerized tomography (CT) consistent with liver cirrhosis AND at least one solid liver lesion > 2 cm with early enhancement and delayed enhancement washout regardless of alpha-feto protein levels (AFP)
    • AFP > 400 ng/mL AND evidence of at least one solid liver lesion > 2 cm regardless of specific imaging characteristics on CT or MRI
  • Patients must have hepatocellular carcinoma (HCC) limited to the liver; there must be no clinical or radiographic evidence of extrahepatic HCC
  • Portal lymphadenopathy IS permitted for patients with hepatitis B virus (HBV) or hepatitis C virus (HCV) - as lymphadenopathy is commonly associated with hepatitis unrelated to malignancy
  • Staging CT of the chest and CT or MRI of the abdomen and pelvis must have been completed within 4 weeks of study registration
  • Patients must have measurable disease constituting < 50% of liver parenchyma within 4 weeks of registration
  • Patients may not have ascites detectable on physical examination
  • Patients must not be candidates for curative resection, orthotopic liver transplantation, or radiofrequency ablation (RFA)
  • Patients may have been treated with RFA in the past, but no sooner than 4 weeks before study registration
  • Patients may have undergone previously attempted curative liver resection
  • Patients may NOT have been previously treated with brachytherapy such as yttrium-90 microsphere
  • Patients may NOT have been previously treated with sorafenib, chemoembolization, or systemic chemotherapy including cytotoxic agents or molecularly targeted agents
  • Branch portal vein invasion by tumor is permitted but patients with main portal vein invasion by tumor are not eligible
  • Patients must have Child-Pugh score of A or B7 within 4 weeks prior to study registration
  • Serum total bilirubin =< 2.0 mg/dL
  • Alkaline phosphatase < 5 x upper limit of normal (ULN)
  • Aspartate aminotransferase (AST), alanine aminotransferase (ALT) < 5 x ULN
  • Serum creatinine =< 1.5 mg/dL
  • Platelet count >= 50,000/mm^3
  • Patients must not have any evidence of bleeding diathesis or active gastrointestinal bleeding
  • Patients must have no clinical signs of heart failure and meet New York Heart Association functional classification I or II defined as:

    • Class I - patients with no limitation of activities; they suffer no symptoms from ordinary activities
    • Class II - patients with slight, mild limitation of activity; they are comfortable with rest or with mild exertion
  • Patients must have an ECOG performance status of 0 or 1
  • Patients must have a life expectancy of at least 3 months
  • Patients must not be known to be human immunodeficiency virus (HIV) positive
  • Patients must not have other uncontrolled intercurrent illnesses excluding HBV or HCV, including, but not limited to: uncontrolled hypertension, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia or psychiatric illness/addictive disorders that would limit compliance with study requirements

    • Uncontrolled hypertension is defined as optimally treated baseline blood pressure that exceeds 150/90 mm Hg
  • Patients must not be taking cytochrome P450 enzyme inducing drugs
  • Women must not be pregnant or breast-feeding; all females of childbearing potential must have a blood test or urine study within 2 weeks prior to registration to rule out pregnancy
  • Women of childbearing potential and sexually active males must be strongly advised to use an accepted and effective method of contraception
  • Patients must not have an allergy to iodine or gadolinium contrast that cannot be safely controlled with premedication
  • Patient must be able to swallow pills, as study medications cannot be crushed
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01004978

  Hide Study Locations
Locations
United States, Alabama
University of Alabama at Birmingham Recruiting
Birmingham, Alabama, United States, 35294
Contact: Carla I. Falkson    205-934-0309      
Principal Investigator: Carla I. Falkson         
University of South Alabama Mitchell Cancer Institute Active, not recruiting
Mobile, Alabama, United States, 36688
United States, Arizona
Mayo Clinic in Arizona Active, not recruiting
Scottsdale, Arizona, United States, 85259
Arizona Cancer Center at UMC Orange Grove Active, not recruiting
Tucson, Arizona, United States, 85704
Arizona Cancer Center at University Medical Center North Active, not recruiting
Tucson, Arizona, United States, 85719
University of Arizona Health Sciences Center Active, not recruiting
Tucson, Arizona, United States, 85724
United States, Arkansas
University of Arkansas for Medical Sciences Recruiting
Little Rock, Arkansas, United States, 72205
Contact: Rangaswamy Govindarajan    501-686-8274      
Principal Investigator: Rangaswamy Govindarajan         
Veteran's Administration Medical Center Active, not recruiting
Little Rock, Arkansas, United States, 72205
United States, California
Marin Cancer Care Inc Recruiting
Greenbrae, California, United States, 94904
Contact: Peter D. Eisenberg    415-925-5000    info@marinspecialtycare.com   
Principal Investigator: Peter D. Eisenberg         
University of Southern California/Norris Cancer Center Recruiting
Los Angeles, California, United States, 90033
Contact: Anthony El-Khoueiry    323-865-0451      
Principal Investigator: Anthony El-Khoueiry         
Saint Joseph Hospital - Orange Active, not recruiting
Orange, California, United States, 92868
UCSF Medical Center-Mount Zion Recruiting
San Francisco, California, United States, 94115
Contact: Alan P. Venook    877-827-3222      
Principal Investigator: Alan P. Venook         
San Francisco General Hospital Active, not recruiting
San Francisco, California, United States, 94110
Stanford University Hospitals and Clinics Recruiting
Stanford, California, United States, 94305
Contact: Daniel Y. Sze    650-498-7061    clinicaltrials@med.stanford.edu   
Principal Investigator: Daniel Y. Sze         
United States, Colorado
University of Colorado Cancer Center - Anschutz Cancer Pavilion Withdrawn
Aurora, Colorado, United States, 80045
Memorial Hospital Colorado Springs Withdrawn
Colorado Springs, Colorado, United States, 80909
Porter Adventist Hospital Active, not recruiting
Denver, Colorado, United States, 80210
Saint Mary's Hospital and Regional Medical Center Withdrawn
Grand Junction, Colorado, United States, 81502
United States, Connecticut
Saint Francis Hospital and Medical Center Recruiting
Hartford, Connecticut, United States, 06105
Contact: Philip J. Stella    734-712-4673      
Principal Investigator: Philip J. Stella         
Yale University Recruiting
New Haven, Connecticut, United States, 06520
Contact: Stacey M. Stein    203-785-5702      
Principal Investigator: Stacey M. Stein         
United States, Delaware
Beebe Medical Center Active, not recruiting
Lewes, Delaware, United States, 19958
Christiana Care Health System-Christiana Hospital Active, not recruiting
Newark, Delaware, United States, 19718
United States, District of Columbia
Veterans Affairs Medical Center -Washington DC Active, not recruiting
Washington, District of Columbia, United States, 20422
United States, Florida
Mayo Clinic in Florida Active, not recruiting
Jacksonville, Florida, United States, 32224-9980
Lakeland Regional Cancer Center Active, not recruiting
Lakeland, Florida, United States, 33805
United States, Georgia
Emory University/Winship Cancer Institute Active, not recruiting
Atlanta, Georgia, United States, 30322
Medical Center of Central Georgia Active, not recruiting
Macon, Georgia, United States, 31208
United States, Hawaii
Pali Momi Medical Center Active, not recruiting
Aiea, Hawaii, United States, 96701
The Cancer Center of Hawaii-Liliha Active, not recruiting
Honolulu, Hawaii, United States, 96817
Queen's Medical Center Active, not recruiting
Honolulu, Hawaii, United States, 96813
Oncare Hawaii Inc-POB II Active, not recruiting
Honolulu, Hawaii, United States, 96813
OnCare Hawaii-Liliha Active, not recruiting
Honolulu, Hawaii, United States, 96817-3169
Kapiolani Medical Center for Women and Children Active, not recruiting
Honolulu, Hawaii, United States, 96826
University of Hawaii Cancer Center Active, not recruiting
Honolulu, Hawaii, United States, 96813
Oncare Hawaii Inc-Kuakini Active, not recruiting
Honolulu, Hawaii, United States, 96817
Castle Medical Center Terminated
Kailua, Hawaii, United States, 96734
Wilcox Memorial Hospital and Kauai Medical Clinic Active, not recruiting
Lihue, Hawaii, United States, 96766
United States, Idaho
Saint Alphonsus Cancer Care Center-Boise Recruiting
Boise, Idaho, United States, 83706
Contact: Philip J. Stella    734-712-4673      
Principal Investigator: Philip J. Stella         
Saint Luke's Mountain States Tumor Institute Recruiting
Boise, Idaho, United States, 83712
Contact: Paul G. Montgomery    800-845-4624      
Principal Investigator: Paul G. Montgomery         
Saint Luke's Mountain States Tumor Institute - Fruitland Recruiting
Fruitland, Idaho, United States, 83619
Contact: Paul G. Montgomery    800-845-4624      
Principal Investigator: Paul G. Montgomery         
Saint Luke's Mountain States Tumor Institute - Meridian Recruiting
Meridian, Idaho, United States, 83642
Contact: Paul G. Montgomery    800-845-4624      
Principal Investigator: Paul G. Montgomery         
Saint Luke's Mountain States Tumor Institute - Nampa Recruiting
Nampa, Idaho, United States, 83686
Contact: Paul G. Montgomery    800-845-4624      
Principal Investigator: Paul G. Montgomery         
Saint Luke's Mountain States Tumor Institute-Twin Falls Recruiting
Twin Falls, Idaho, United States, 83301
Contact: Paul G. Montgomery    800-845-4624      
Principal Investigator: Paul G. Montgomery         
United States, Illinois
Saint Joseph Medical Center Recruiting
Bloomington, Illinois, United States, 61701
Contact: Nguyet A. Le-Lindqwister    800-793-2262      
Principal Investigator: Nguyet A. Le-Lindqwister         
Illinois CancerCare-Bloomington Active, not recruiting
Bloomington, Illinois, United States, 61701
Graham Hospital Association Terminated
Canton, Illinois, United States, 61520
Illinois CancerCare-Canton Active, not recruiting
Canton, Illinois, United States, 61520
Illinois CancerCare-Carthage Active, not recruiting
Carthage, Illinois, United States, 62321
Memorial Hospital Terminated
Carthage, Illinois, United States, 62321
Northwestern University Active, not recruiting
Chicago, Illinois, United States, 60611
University of Chicago Active, not recruiting
Chicago, Illinois, United States, 60637
Swedish Covenant Hospital Active, not recruiting
Chicago, Illinois, United States, 60625
University of Illinois Active, not recruiting
Chicago, Illinois, United States, 60612
John H Stroger Jr Hospital of Cook County Active, not recruiting
Chicago, Illinois, United States, 60612-3785
Hematology and Oncology Associates Terminated
Chicago, Illinois, United States, 60611
Illinois CancerCare-Eureka Active, not recruiting
Eureka, Illinois, United States, 61530
Eureka Hospital Active, not recruiting
Eureka, Illinois, United States, 61530
Saint Francis Hospital Active, not recruiting
Evanston, Illinois, United States, 60202
Illinois CancerCare-Galesburg Cottage Plaza Office Recruiting
Galesburg, Illinois, United States, 61401
Contact: Nguyet A. Le-Lindqwister    800-793-2262      
Principal Investigator: Nguyet A. Le-Lindqwister         
Illinois CancerCare Galesburg Recruiting
Galesburg, Illinois, United States, 61401
Contact: Nguyet A. Le-Lindqwister    800-793-2262      
Principal Investigator: Nguyet A. Le-Lindqwister         
Ingalls Memorial Hospital Active, not recruiting
Harvey, Illinois, United States, 60426
Mason District Hospital Terminated
Havana, Illinois, United States, 62644
Illinois CancerCare-Havana Terminated
Havana, Illinois, United States, 62644
Hematology Oncology Associates of Illinois-Highland Park Active, not recruiting
Highland Park, Illinois, United States, 60035
Hines Veterans Administration Hospital Active, not recruiting
Hines, Illinois, United States, 60141
Hinsdale Hematology Oncology Associates Incorporated Active, not recruiting
Hinsdale, Illinois, United States, 60521
Midwest Center for Hematology Oncology Terminated
Joliet, Illinois, United States, 60432
Presence Saint Mary's Hospital Active, not recruiting
Kankakee, Illinois, United States, 60901
Illinois CancerCare-Kewanee Clinic Active, not recruiting
Kewanee, Illinois, United States, 61443
Adventist La Grange Memorial Hospital Recruiting
La Grange, Illinois, United States, 60525
Contact: Renee H. Jacobs    630-856-7526      
Principal Investigator: Renee H. Jacobs         
North Shore Hematology Oncology Active, not recruiting
Libertyville, Illinois, United States, 60048
Mcdonough District Hospital Terminated
Macomb, Illinois, United States, 61455
Illinois CancerCare-Macomb Active, not recruiting
Macomb, Illinois, United States, 61455
Loyola University Medical Center Withdrawn
Maywood, Illinois, United States, 60153
Holy Family Medical Center Terminated
Monmouth, Illinois, United States, 61462
Illinois CancerCare-Monmouth Terminated
Monmouth, Illinois, United States, 61462
Illinois Cancer Specialists-Niles Active, not recruiting
Niles, Illinois, United States, 60714
Community Cancer Center Foundation Terminated
Normal, Illinois, United States, 61761
Illinois CancerCare-Community Cancer Center Terminated
Normal, Illinois, United States, 61761
Bromenn Regional Medical Center Terminated
Normal, Illinois, United States, 61761
Ottawa Regional Hospital and Healthcare Center Active, not recruiting
Ottawa, Illinois, United States, 61350
Illinois CancerCare-Ottawa Clinic Active, not recruiting
Ottawa, Illinois, United States, 61350
Pekin Hospital Terminated
Pekin, Illinois, United States, 61554
Pekin Cancer Treatment Center Recruiting
Pekin, Illinois, United States, 61554
Contact: Nguyet A. Le-Lindqwister    800-793-2262      
Principal Investigator: Nguyet A. Le-Lindqwister         
Illinois CancerCare-Pekin Active, not recruiting
Pekin, Illinois, United States, 61554
Illinois CancerCare-Peoria Recruiting
Peoria, Illinois, United States, 61615
Contact: Nguyet A. Le-Lindqwister    800-793-2262      
Principal Investigator: Nguyet A. Le-Lindqwister         
Proctor Hospital Terminated
Peoria, Illinois, United States, 61614
Illinois Oncology Research Association CCOP Terminated
Peoria, Illinois, United States, 61615
Methodist Medical Center of Illinois Recruiting
Peoria, Illinois, United States, 61603
Contact: Nguyet A. Le-Lindqwister    800-793-2262      
Principal Investigator: Nguyet A. Le-Lindqwister         
OSF Saint Francis Medical Center Recruiting
Peoria, Illinois, United States, 61637
Contact: Nguyet A. Le-Lindqwister    800-793-2262      
Principal Investigator: Nguyet A. Le-Lindqwister         
Illinois CancerCare-Peru Active, not recruiting
Peru, Illinois, United States, 61354
Illinois Valley Hospital Terminated
Peru, Illinois, United States, 61354
Illinois CancerCare-Princeton Active, not recruiting
Princeton, Illinois, United States, 61356
Perry Memorial Hospital Terminated
Princeton, Illinois, United States, 61356
West Suburban Medical Center Withdrawn
River Forest, Illinois, United States, 60305
Swedish American Hospital Withdrawn
Rockford, Illinois, United States, 61104
SwedishAmerican Regional Cancer Center/ACT Active, not recruiting
Rockford, Illinois, United States, 61107
Hematology Oncology Associates of Illinois - Skokie Active, not recruiting
Skokie, Illinois, United States, 60076
Illinois CancerCare-Spring Valley Terminated
Spring Valley, Illinois, United States, 61362
United States, Iowa
Medical Oncology and Hematology Associates-West Des Moines Active, not recruiting
Clive, Iowa, United States, 50325
Iowa Lutheran Hospital Active, not recruiting
Des Moines, Iowa, United States, 50316
Mercy Medical Center - Des Moines Active, not recruiting
Des Moines, Iowa, United States, 50314
Medical Oncology and Hematology Associates-Laurel Active, not recruiting
Des Moines, Iowa, United States, 50314
Iowa Methodist Medical Center Active, not recruiting
Des Moines, Iowa, United States, 50309
Medical Oncology and Hematology Associates-Des Moines Active, not recruiting
Des Moines, Iowa, United States, 50309
Iowa Oncology Research Association CCOP Active, not recruiting
Des Moines, Iowa, United States, 50309
United States, Kansas
Hays Medical Center Recruiting
Hays, Kansas, United States, 67601
Contact: Peter J. Van Veldhuizen    800-525-1483      
Principal Investigator: Peter J. Van Veldhuizen         
Promise Regional Medical Center-Hutchinson Terminated
Hutchinson, Kansas, United States, 65702
Kansas City Cancer Center-West Recruiting
Kansas City, Kansas, United States, 66112
Contact: Peter J. Van Veldhuizen    800-525-1483      
Principal Investigator: Peter J. Van Veldhuizen         
University of Kansas Medical Center Recruiting
Kansas City, Kansas, United States, 66160
Contact: Peter J. Van Veldhuizen    800-525-1483      
Principal Investigator: Peter J. Van Veldhuizen         
Menorah Medical Center Active, not recruiting
Overland Park, Kansas, United States, 66209
Saint Luke's South Hospital Active, not recruiting
Overland Park, Kansas, United States, 66213
Kansas City Cancer Centers-Southwest Recruiting
Overland Park, Kansas, United States, 66210
Contact: Peter J. Van Veldhuizen    800-525-1483      
Principal Investigator: Peter J. Van Veldhuizen         
Via Christi Hospital-Pittsburg Recruiting
Pittsburg, Kansas, United States, 66762
Contact: Peter J. Van Veldhuizen    800-525-1483      
Principal Investigator: Peter J. Van Veldhuizen         
Kansas City CCOP Terminated
Prairie Village, Kansas, United States, 66208
Salina Regional Health Center Recruiting
Salina, Kansas, United States, 67401
Contact: Peter J. Van Veldhuizen    800-525-1483      
Principal Investigator: Peter J. Van Veldhuizen         
Shawnee Mission Medical Center Terminated
Shawnee Mission, Kansas, United States, 66204
Kansas City Cancer Center-Shawnee Mission Recruiting
Shawnee Mission, Kansas, United States, 66204
Contact: Peter J. Van Veldhuizen    800-525-1483      
Principal Investigator: Peter J. Van Veldhuizen         
Saint Francis Hospital and Medical Center - Topeka Recruiting
Topeka, Kansas, United States, 66606
Contact: Peter J. Van Veldhuizen    800-525-1483      
Principal Investigator: Peter J. Van Veldhuizen         
United States, Kentucky
University of Kentucky Recruiting
Lexington, Kentucky, United States, 40536
Contact: John J. Rinehart    859-257-3379      
Principal Investigator: John J. Rinehart         
United States, Louisiana
Ochsner Medical Center Jefferson Recruiting
New Orleans, Louisiana, United States, 70121
Contact: Jyotsna Fuloria    888-562-4763      
Principal Investigator: Jyotsna Fuloria         
Louisiana State University Health Sciences Center Shreveport Withdrawn
Shreveport, Louisiana, United States, 71130
United States, Maryland
Johns Hopkins University/Sidney Kimmel Comprehensive Cancer Center Active, not recruiting
Baltimore, Maryland, United States, 21287
Saint Agnes Hospital Recruiting
Baltimore, Maryland, United States, 21229
Contact: Carole B. Miller    410-368-2910      
Principal Investigator: Carole B. Miller         
Union Hospital of Cecil County Active, not recruiting
Elkton MD, Maryland, United States, 21921
United States, Massachusetts
Tufts Medical Center Recruiting
Boston, Massachusetts, United States, 02111
Contact: Kevin P. Daly    617-636-5000    ContactUsCancerCenter@TuftsMedicalCenter.org   
Principal Investigator: Kevin P. Daly         
Boston Medical Center Active, not recruiting
Boston, Massachusetts, United States, 02118
Lahey Hospital and Medical Center Active, not recruiting
Burlington, Massachusetts, United States, 01805
United States, Michigan
University of Michigan Active, not recruiting
Ann Arbor, Michigan, United States, 48109
University of Michigan University Hospital Recruiting
Ann Arbor, Michigan, United States, 48109
Contact: Jean-Francois (Jeff) H. Geschwind    410-955-8804      
Principal Investigator: Jean-Francois (Jeff) H. Geschwind         
Michigan Cancer Research Consortium Community Clinical Oncology Program Terminated
Ann Arbor, Michigan, United States, 48106
Saint Joseph Mercy Hospital Active, not recruiting
Ann Arbor, Michigan, United States, 48106-0995
Oakwood Hospital and Medical Center Active, not recruiting
Dearborn, Michigan, United States, 48124
Saint John Hospital and Medical Center Active, not recruiting
Detroit, Michigan, United States, 48236
Hurley Medical Center Active, not recruiting
Flint, Michigan, United States, 48502
Genesys Regional Medical Center-West Flint Campus Withdrawn
Flint, Michigan, United States, 48532
Allegiance Health Active, not recruiting
Jackson, Michigan, United States, 49201
Borgess Medical Center Active, not recruiting
Kalamazoo, Michigan, United States, 49001
West Michigan Cancer Center Active, not recruiting
Kalamazoo, Michigan, United States, 49007
Bronson Methodist Hospital Active, not recruiting
Kalamazoo, Michigan, United States, 49007
Sparrow Hospital Active, not recruiting
Lansing, Michigan, United States, 48912
Saint Mary Mercy Hospital Recruiting
Livonia, Michigan, United States, 48154
Contact: Philip J. Stella    734-712-4673      
Principal Investigator: Philip J. Stella         
Marquette General Hospital Withdrawn
Marquette, Michigan, United States, 49855
Saint Joseph Mercy Oakland Active, not recruiting
Pontiac, Michigan, United States, 48341-2985
Saint Joseph Mercy Port Huron Active, not recruiting
Port Huron, Michigan, United States, 48060
Saint Mary's of Michigan Recruiting
Saginaw, Michigan, United States, 48601
Contact: Philip J. Stella    734-712-4673      
Principal Investigator: Philip J. Stella         
Providence Hospital Active, not recruiting
Southfield, Michigan, United States, 48075
Saint John Macomb-Oakland Hospital Active, not recruiting
Warren, Michigan, United States, 48093
United States, Minnesota
Fairview Ridges Hospital Active, not recruiting
Burnsville, Minnesota, United States, 55337
Mercy Hospital Active, not recruiting
Coon Rapids, Minnesota, United States, 55433
Fairview-Southdale Hospital Active, not recruiting
Edina, Minnesota, United States, 55435
Unity Hospital Active, not recruiting
Fridley, Minnesota, United States, 55432
Hutchinson Area Health Care Active, not recruiting
Hutchinson, Minnesota, United States, 55350
Saint John's Hospital - Healtheast Active, not recruiting
Maplewood, Minnesota, United States, 55109
Minnesota Oncology Hematology PA-Maplewood Active, not recruiting
Maplewood, Minnesota, United States, 55109
Abbott-Northwestern Hospital Active, not recruiting
Minneapolis, Minnesota, United States, 55407
Hennepin County Medical Center Active, not recruiting
Minneapolis, Minnesota, United States, 55415
North Memorial Medical Health Center Active, not recruiting
Robbinsdale, Minnesota, United States, 55422
Park Nicollet Clinic - Saint Louis Park Active, not recruiting
Saint Louis Park, Minnesota, United States, 55416
Metro-Minnesota CCOP Terminated
Saint Louis Park, Minnesota, United States, 55416
Regions Hospital Active, not recruiting
Saint Paul, Minnesota, United States, 55101
United Hospital Active, not recruiting
Saint Paul, Minnesota, United States, 55102
Saint Francis Regional Medical Center Active, not recruiting
Shakopee, Minnesota, United States, 55379
Ridgeview Medical Center Active, not recruiting
Waconia, Minnesota, United States, 55387
Rice Memorial Hospital Active, not recruiting
Willmar, Minnesota, United States, 56201
Minnesota Oncology and Hematology PA-Woodbury Active, not recruiting
Woodbury, Minnesota, United States, 55125
United States, Mississippi
University of Mississippi Medical Center Active, not recruiting
Jackson, Mississippi, United States, 39216
United States, Missouri
Veterans Administration Active, not recruiting
Columbia, Missouri, United States, 65201
Kansas City Cancer Centers - North Recruiting
Kansas City, Missouri, United States, 64154
Contact: Peter J. Van Veldhuizen    800-525-1483      
Principal Investigator: Peter J. Van Veldhuizen         
Research Medical Center Active, not recruiting
Kansas City, Missouri, United States, 64132
Kansas City Veterans Affairs Medical Center Active, not recruiting
Kansas City, Missouri, United States, 64128
Heartland Hematology and Oncology Associates Incorporated Active, not recruiting
Kansas City, Missouri, United States, 64118
Saint Luke's Hospital of Kansas City Recruiting
Kansas City, Missouri, United States, 64111
Contact: Rakesh Gaur    913-948-5588    aroland@kccop.org   
Principal Investigator: Rakesh Gaur         
Saint Joseph Health Center Terminated
Kansas City, Missouri, United States, 64114
Truman Medical Center Recruiting
Kansas City, Missouri, United States, 64108
Contact: Peter J. Van Veldhuizen    800-525-1483      
Principal Investigator: Peter J. Van Veldhuizen         
North Kansas City Hospital Terminated
Kansas City, Missouri, United States, 64116
Kansas City Cancer Center - South Recruiting
Kansas City, Missouri, United States, 64131
Contact: Peter J. Van Veldhuizen    800-525-1483      
Principal Investigator: Peter J. Van Veldhuizen         
Kansas City Cancer Center-Lee's Summit Recruiting
Lee's Summit, Missouri, United States, 64064
Contact: Peter J. Van Veldhuizen    800-525-1483      
Principal Investigator: Peter J. Van Veldhuizen         
Saint Luke's East - Lee's Summit Active, not recruiting
Lee's Summit, Missouri, United States, 64086
Liberty Hospital Withdrawn
Liberty, Missouri, United States, 64068
Heartland Regional Medical Center Active, not recruiting
Saint Joseph, Missouri, United States, 64506
Saint Joseph Oncology Inc Terminated
Saint Joseph, Missouri, United States, 64507
Washington University School of Medicine Recruiting
Saint Louis, Missouri, United States, 63110
Contact: Benjamin R. Tan    800-600-3606    info@siteman.wustl.edu   
Principal Investigator: Benjamin R. Tan         
United States, Montana
Billings Clinic Active, not recruiting
Billings, Montana, United States, 59107-7000
Northern Rockies Radiation Oncology Center Terminated
Billings, Montana, United States, 59101
Montana Cancer Consortium CCOP Active, not recruiting
Billings, Montana, United States, 59101
Saint Vincent Healthcare Active, not recruiting
Billings, Montana, United States, 59101
Hematology-Oncology Centers of the Northern Rockies PC Terminated
Billings, Montana, United States, 59102
Bozeman Deaconess Cancer Center Withdrawn
Bozeman, Montana, United States, 59715
Bozeman Deaconess Hospital Active, not recruiting
Bozeman, Montana, United States, 59715
Saint James Community Hospital and Cancer Treatment Center Active, not recruiting
Butte, Montana, United States, 59701
Great Falls Clinic Terminated
Great Falls, Montana, United States, 59405
Berdeaux, Donald MD (UIA Investigator) Terminated
Great Falls, Montana, United States, 59405
Benefis Healthcare- Sletten Cancer Institute Active, not recruiting
Great Falls, Montana, United States, 59405
Northern Montana Hospital Terminated
Havre, Montana, United States, 59501
Saint Peter's Community Hospital Active, not recruiting
Helena, Montana, United States, 59601
Glacier Oncology PLLC Terminated
Kalispell, Montana, United States, 59901
Kalispell Medical Oncology Terminated
Kalispell, Montana, United States, 59901
Kalispell Regional Medical Center Active, not recruiting
Kalispell, Montana, United States, 59901
Montana Cancer Specialists Terminated
Missoula, Montana, United States, 59802
Saint Patrick Hospital - Community Hospital Active, not recruiting
Missoula, Montana, United States, 59802
Guardian Oncology and Center for Wellness Terminated
Missoula, Montana, United States, 59804
Community Medical Hospital Active, not recruiting
Missoula, Montana, United States, 59801
United States, Nebraska
Saint Francis Medical Center Active, not recruiting
Grand Island, Nebraska, United States, 68803
Great Plains Regional Medical Center Active, not recruiting
North Platte, Nebraska, United States, 69103
University of Nebraska Medical Center Active, not recruiting
Omaha, Nebraska, United States, 68198
Nebraska Methodist Hospital Active, not recruiting
Omaha, Nebraska, United States, 68114
United States, Nevada
Renown Regional Medical Center Recruiting
Reno, Nevada, United States, 89502
Contact: Christos A. Galanopoulos    775-982-4400      
Principal Investigator: Christos A. Galanopoulos         
United States, New Hampshire
Dartmouth Hitchcock Medical Center Withdrawn
Lebanon, New Hampshire, United States, 03756
United States, New Jersey
Cooper Hospital University Medical Center Active, not recruiting
Camden, New Jersey, United States, 08103
Fox Chase Cancer Center at Virtua Memorial Hospital of Burlington County Withdrawn
Mount Holly, New Jersey, United States, 08060
UMDNJ - New Jersey Medical School Active, not recruiting
Newark, New Jersey, United States, 07103
Virtua West Jersey Hospital Voorhees Withdrawn
Voorhees, New Jersey, United States, 08043
MD Anderson Cancer Center at Cooper-Voorhees Active, not recruiting
Voorhees, New Jersey, United States, 08043
United States, New Mexico
University of New Mexico Active, not recruiting
Albuquerque, New Mexico, United States, 87106
United States, New York
Veteran Affairs New York Harbor Healthcare System-Brooklyn Campus Active, not recruiting
Brooklyn, New York, United States, 11209
Maimonides Medical Center Active, not recruiting
Brooklyn, New York, United States, 11219
New York University Langone Medical Center Recruiting
New York, New York, United States, 10016
Contact: George Miller    212-263-4434    prmc.coordinator@nyumc.org   
Principal Investigator: George Miller         
Saint Luke's Roosevelt Hospital Center - Saint Luke's Division Active, not recruiting
New York, New York, United States, 10025
Beth Israel Medical Center Active, not recruiting
New York, New York, United States, 10003
Veterans Affairs New York Harbor Healthcare System-Manhattan Campus Active, not recruiting
New York, New York, United States, 10010
United States, North Carolina
University of North Carolina Recruiting
Chapel Hill, North Carolina, United States, 27599
Contact: Cheryl A. Carlson    877-668-0683    cancerclinicaltrials@med.unc.edu   
Principal Investigator: Cheryl A. Carlson         
Novant Health Presbyterian Medical Center Active, not recruiting
Charlotte, North Carolina, United States, 28204
Rutherford Hospital Withdrawn
Rutherfordton, North Carolina, United States, 28139
Wake Forest University Health Sciences Active, not recruiting
Winston-Salem, North Carolina, United States, 27157
United States, Ohio
University of Cincinnati Active, not recruiting
Cincinnati, Ohio, United States, 45267
Case Western Reserve University Active, not recruiting
Cleveland, Ohio, United States, 44106
MetroHealth Medical Center Recruiting
Cleveland, Ohio, United States, 44109
Contact: Bruce J. Averbook    216-778-8526    kbauchens@metrohealth.org   
Principal Investigator: Bruce J. Averbook         
Cleveland Clinic Foundation Recruiting
Cleveland, Ohio, United States, 44195
Contact: Anjali S. Advani    866-223-8100      
Principal Investigator: Anjali S. Advani         
Ohio State University Medical Center Recruiting
Columbus, Ohio, United States, 43210
Contact: Carl R. Schmidt    866-627-7616    osu@emergingmed.com   
Principal Investigator: Carl R. Schmidt         
Flower Hospital Active, not recruiting
Sylvania, Ohio, United States, 43560
University of Toledo Active, not recruiting
Toledo, Ohio, United States, 43614
Mercy Saint Anne Hospital Active, not recruiting
Toledo, Ohio, United States, 43623
United States, Oklahoma
University of Oklahoma Health Sciences Center Recruiting
Oklahoma City, Oklahoma, United States, 73104
Contact: Shubham Pant    405-271-4272    julie-traylor@ouhsc.edu   
Principal Investigator: Shubham Pant         
Tulsa Cancer Institute Recruiting
Tulsa, Oklahoma, United States, 74146
Contact: Shubham Pant    405-271-4272    julie-traylor@ouhsc.edu   
Principal Investigator: Shubham Pant         
United States, Oregon
Legacy Mount Hood Medical Center Active, not recruiting
Gresham, Oregon, United States, 97030
Legacy Good Samaritan Hospital and Medical Center Active, not recruiting
Portland, Oregon, United States, 97210
Legacy Emanuel Hospital and Health Center Active, not recruiting
Portland, Oregon, United States, 97227
Legacy Meridian Park Hospital Active, not recruiting
Tualatin, Oregon, United States, 97062
United States, Pennsylvania
Geisinger Medical Center Recruiting
Danville, Pennsylvania, United States, 17822-2001
Contact: Edward J. Gorak    570-271-5251      
Principal Investigator: Edward J. Gorak         
Thomas Jefferson University Hospital Recruiting
Philadelphia, Pennsylvania, United States, 19107
Contact: Ashwin R. Sama    215-955-6084      
Principal Investigator: Ashwin R. Sama         
Fox Chase Cancer Center Recruiting
Philadelphia, Pennsylvania, United States, 19111
Contact: Crystal S. Denlinger    215-728-4790      
Principal Investigator: Crystal S. Denlinger         
Albert Einstein Medical Center Active, not recruiting
Philadelphia, Pennsylvania, United States, 19141
United States, Rhode Island
Roger Williams Hospital Active, not recruiting
Providence, Rhode Island, United States, 02908
United States, South Carolina
AnMed Health Cancer Center Recruiting
Anderson, South Carolina, United States, 29621
Contact: Charles E. Bowers    800-486-5941      
Principal Investigator: Charles E. Bowers         
AnMed Health Hospital Recruiting
Anderson, South Carolina, United States, 29621
Contact: Charles E. Bowers    800-486-5941      
Principal Investigator: Charles E. Bowers         
Medical University of South Carolina Recruiting
Charleston, South Carolina, United States, 29425
Contact: Melanie B. Thomas    843-792-9321      
Principal Investigator: Melanie B. Thomas         
Greenville Health System Cancer Institute-Easley Active, not recruiting
Easley, South Carolina, United States, 29640
Saint Francis Hospital Active, not recruiting
Greenville, South Carolina, United States, 29601
Greenville Health System Cancer Institute-Andrews Active, not recruiting
Greenville, South Carolina, United States, 29605
Greenville Health System Cancer Institute-Greer Active, not recruiting
Greer, South Carolina, United States, 29650
Spartanburg Regional Medical Center Recruiting
Spartanburg, South Carolina, United States, 29303
Contact: Charles E. Bowers    800-486-5941      
Principal Investigator: Charles E. Bowers         
Upstate Carolina CCOP Recruiting
Spartanburg, South Carolina, United States, 29303
Contact: Charles E. Bowers    800-486-5941      
Principal Investigator: Charles E. Bowers         
United States, Tennessee
Jackson-Madison County General Hospital Withdrawn
Jackson, Tennessee, United States, 38301
University of Tennessee - Knoxville Active, not recruiting
Knoxville, Tennessee, United States, 37920
United States, Texas
The Don and Sybil Harrington Cancer Center Recruiting
Amarillo, Texas, United States, 79106
Contact: Stewart A. Sharp    806-359-4673    ryokubaitis@harringtoncc.org   
Principal Investigator: Stewart A. Sharp         
University of Texas Medical Branch at Galveston Terminated
Galveston, Texas, United States, 77555-0565
United States, Utah
Huntsman Cancer Institute/University of Utah Active, not recruiting
Salt Lake City, Utah, United States, 84112
United States, Virginia
Bon Secours Saint Francis Medical Center Recruiting
Midlothian, Virginia, United States, 23114
Contact: William J. Irvin    804-594-4900      
Principal Investigator: William J. Irvin         
Virginia Commonwealth University Recruiting
Richmond, Virginia, United States, 23298
Contact: Andrew Poklepovic    804-628-1939      
Principal Investigator: Andrew Poklepovic         
Bon Secours Saint Mary's Hospital Recruiting
Richmond, Virginia, United States, 23226
Contact: William J. Irvin    804-594-4900      
Principal Investigator: William J. Irvin         
Hunter Holmes McGuire Veterans Administration Medical Center Active, not recruiting
Richmond, Virginia, United States, 23249
United States, Washington
Auburn Regional Medical Center Recruiting
Auburn, Washington, United States, 98001
Contact: John A. Keech    253-887-9333      
Principal Investigator: John A. Keech         
Highline Medical Center-Main Campus Active, not recruiting
Burien, Washington, United States, 98166
Providence Regional Cancer System-Centralia Recruiting
Centralia, Washington, United States, 98531
Contact: John A. Keech    253-887-9333      
Principal Investigator: John A. Keech         
Providence Regional Cancer Partnership Recruiting
Everett, Washington, United States, 98201
Contact: John A. Keech    253-887-9333      
Principal Investigator: John A. Keech         
Saint Francis Hospital Active, not recruiting
Federal Way, Washington, United States, 98003
Saint Clare Hospital Recruiting
Lakewood, Washington, United States, 98499
Contact: John A. Keech    253-887-9333      
Principal Investigator: John A. Keech         
Providence - Saint Peter Hospital Terminated
Olympia, Washington, United States, 98506-5166
Good Samaritan Community Hospital Recruiting
Puyallup, Washington, United States, 98372
Contact: John A. Keech    253-887-9333      
Principal Investigator: John A. Keech         
Virginia Mason CCOP Recruiting
Seattle, Washington, United States, 98101
Contact: Craig R. Nichols    503-215-6412      
Principal Investigator: Craig R. Nichols         
Virginia Mason Medical Center Terminated
Seattle, Washington, United States, 98101
Group Health Cooperative-Seattle Active, not recruiting
Seattle, Washington, United States, 98112
Allenmore Hospital Terminated
Tacoma, Washington, United States, 98405
Multicare Health System Recruiting
Tacoma, Washington, United States, 98415
Contact: John A. Keech    253-887-9333      
Principal Investigator: John A. Keech         
Northwest CCOP Terminated
Tacoma, Washington, United States, 98405
Saint Joseph Medical Center Terminated
Tacoma, Washington, United States, 98405
Legacy Salmon Creek Hospital Active, not recruiting
Vancouver, Washington, United States, 98686
United States, West Virginia
West Virginia University Healthcare Recruiting
Morgantown, West Virginia, United States, 26506
Contact: Brent T. Steadman    304-293-2745    sfilburn@hsc.wvu.edu   
Principal Investigator: Brent T. Steadman         
Princeton Community Hospital Active, not recruiting
Princeton, West Virginia, United States, 24740
United States, Wisconsin
University of Wisconsin Hospital and Clinics Active, not recruiting
Madison, Wisconsin, United States, 53792
Marshfield Clinic Recruiting
Marshfield, Wisconsin, United States, 54449
Contact: Kristin M. Gerndt    715-389-4457      
Principal Investigator: Kristin M. Gerndt         
Froedtert and the Medical College of Wisconsin Recruiting
Milwaukee, Wisconsin, United States, 53226
Contact: Benjamin J. George    888-785-6789      
Principal Investigator: Benjamin J. George         
United States, Wyoming
Rocky Mountain Oncology Terminated
Casper, Wyoming, United States, 82609
Welch Cancer Center Active, not recruiting
Sheridan, Wyoming, United States, 82801
Sponsors and Collaborators
Investigators
Principal Investigator: Jean-Francois (Jeff) Geschwind ECOG-ACRIN Cancer Research Group
  More Information

No publications provided

Responsible Party: National Cancer Institute (NCI)
ClinicalTrials.gov Identifier: NCT01004978     History of Changes
Other Study ID Numbers: NCI-2011-01981, NCI-2011-01981, ECOG-E1208, CDR0000657952, E1208, E1208, U10CA021115, U10CA180820
Study First Received: October 29, 2009
Last Updated: October 23, 2014
Health Authority: United States: Food and Drug Administration

Additional relevant MeSH terms:
Carcinoma
Carcinoma, Hepatocellular
Liver Neoplasms
Adenocarcinoma
Digestive System Diseases
Digestive System Neoplasms
Liver Diseases
Neoplasms
Neoplasms by Histologic Type
Neoplasms by Site
Neoplasms, Glandular and Epithelial
Cisplatin
Doxorubicin
Liposomal doxorubicin
Mitomycin
Mitomycins
Niacinamide
Sorafenib
Alkylating Agents
Antibiotics, Antineoplastic
Antineoplastic Agents
Enzyme Inhibitors
Growth Substances
Micronutrients
Molecular Mechanisms of Pharmacological Action
Nucleic Acid Synthesis Inhibitors
Pharmacologic Actions
Physiological Effects of Drugs
Protein Kinase Inhibitors
Radiation-Sensitizing Agents

ClinicalTrials.gov processed this record on October 23, 2014